Clinical trial
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2…
NCT00430742 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00430742 |
|---|---|
| Title | An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED) |
| Official title | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Taranabant, Comparator: Placebo |
| Enrollment | 600 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Feb 13, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: